How Often Will You Be Scanned — on Immunotherapy?

Most patients get a baseline scan before immunotherapy starts, then a first response-assessment scan roughly 8-12 weeks later — about every 2-4 treatment cycles — a pattern that follows NCCN guidance and the iRECIST criteria built specifically for immune-based treatments. This is a common starting rhythm, not a universal rule: the exact spacing depends on your drug, your cancer type, and how your oncologist wants to monitor you.

• Baseline scan — done before or right at the start of treatment, so every later scan has something to compare against.
• First assessment scan — typically 8-12 weeks in, the point where "is it working" gets its first real answer.
• Early-phase scans — usually every 2-3 cycles while decisions about continuing, switching or combining treatment are still being made.
• Your specific protocol matters — a checkpoint inhibitor given every 2, 3 or 6 weeks changes how "every 2-4 cycles" translates into calendar weeks.

This page explains typical scheduling patterns for education only — it does not set or interpret your individual scan schedule or report. That stays with your treating oncologist.

Indicative pattern for patient education, as of August 2026, drawn from commonly cited NCCN-aligned practice. Individual schedules vary by drug, cancer type and how you are responding — your oncologist sets and can change your actual interval at any time.

Yes — scans are usually closest together early on, when the biggest treatment decisions are being made, and space out once your disease shows a stable or responding pattern. Most oncologists move from an 8-12 week rhythm during induction to every 12-16 weeks once you're settled into maintenance immunotherapy, and further out again during long-term surveillance after active treatment ends.

The interval can also shorten again at any point — new symptoms, an abnormal blood test, or a finding on a previous scan that needs a closer look are all reasons your oncologist may bring the next scan forward, regardless of where you are in the "typical" schedule above.

There is no fixed calendar that applies to every patient. Two people on the same drug for the same cancer can have different scan intervals because their disease is behaving differently — that difference is expected, not a sign either person is being under- or over-monitored.

*Indicative, as of August 2026, and centre-dependent — not a CION price list against any single treatment. Across 4-6 scans a year, mostly-CT monitoring adds up to a meaningfully smaller annual sum than a mostly-PET-CT schedule; ask your care team for a written estimate specific to your protocol. PET-CT for CION patients is coordinated at partner imaging centres, not performed in-house. Ask whether Aarogyasri, other government schemes, insurance cashless, or EMI options apply to your monitoring costs.

This mismatch is common enough on immunotherapy that guidelines have a specific name for it: pseudoprogression, where immune activity gathering at the tumour site can briefly make a scan look larger before it actually shrinks. iRECIST criteria were built specifically to handle this — they call for a confirmation scan a few weeks later before "progression" is confirmed, rather than changing your treatment plan off a single scan.

The reverse can happen too: feeling better does not always mean the scan will show a clean improvement, and some genuinely immune-related changes on a scan aren't cancer at all — see Immune-Related Findings on a Scan That Are Not Cancer for how those are told apart. Either way, treat a single scan as one data point your oncologist reads together with how you're doing clinically, not as the whole picture on its own.

If you want help reading what a report actually says, line by line, Understanding Your Response Assessment Report Line by Line walks through the terminology in more depth. Some centres also use circulating tumour DNA (ctDNA) monitoring alongside scans for an additional signal between imaging appointments.

• Understanding Your Response Assessment Report Line by Line — what each section of the report actually means, once the scan is done.
• Circulating Tumour DNA (ctDNA) for Monitoring Response — a blood-based signal some oncologists use between scheduled scans.
• Immune-Related Findings on a Scan That Are Not Cancer — why a scan can show new activity that isn't disease progression.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through treatment and monitoring.

This page explains typical scan-interval patterns and cost ranges for education only, and does not set or interpret any individual patient's scan schedule or report. PET-CT for CION patients is coordinated at partner imaging centres. Bring your treatment plan to a consultation for a schedule and cost estimate specific to you.

Thousands of families have planned their scan journey with us

Not knowing when the next scan is, or what it will cost, adds a quiet stress on top of everything else. Our oncologists lay out both, clearly, from the very first consultation.